NCT04929912 (PIONEER) is a clinical trial in Skin Cancer, sponsored by Mirai Medical.

Who is sponsoring NCT04929912?

NCT04929912 is sponsored by Mirai Medical.

What condition does NCT04929912 study?

NCT04929912 studies Skin Cancer, Gastrointestinal Cancer.

Is NCT04929912 still recruiting?

NCT04929912 is currently recruiting now. Last updated 29 January 2025.

Last reviewed 2025-01-29 · How we verify

NCT04929912: PIONEER

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Electroporation for Cancer Treatment Real World Registry

Recruiting now Last updated 29 January 2025

What this trial tests

trial in Skin Cancer in 1,000 participants. Currently enrolling.

Timeline

24 June 2021

Primary endpoint
24 December 2026

24 June 2036

Quick facts

Lead sponsor	Mirai Medical
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	1,000
Start date	24 June 2021
Primary completion	24 December 2026
Estimated completion	24 June 2036
Sites	1 location across United Kingdom

Conditions studied

Skin Cancer — all drugs for Skin Cancer →
Gastrointestinal Cancer — all drugs for Gastrointestinal Cancer →

Sponsor

Mirai Medical — full company profile →

Who can join

Eligibility, any sex, with Skin Cancer or Gastrointestinal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This registry aims to assess real-world long-term disease outcomes for patients treated using reversible electroporation and a chemotherapeutic or calcium; in particular tumour response rates and recurrence rates. The study also aims to characterise side effects and the occurrence of Adverse Events and their relationship to the treatment.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Skin Cancer

Currently open trials in the same condition.

NCT07288073 — TIL Therapy in cSCC and MCC · Phase 2 · recruiting
NCT06926075 — Early Phase Study of KESONOTIDE™in Participants With Solid Tumours · Phase 1, PHASE2 · recruiting
NCT06932172 — Artificial Intelligent Decision Support for Skin Cancer Diagnostics in Primary Care · NA · recruiting
NCT07510061 — Title: ICARUS - Psycho-physiological Profiling of Low and High Heat-resilient Individuals · NA · recruiting
NCT07200544 — Meloxicam in Mohs Micrographic Surgery · Phase 4 · recruiting

Other Mirai Medical trials

Trials by the same sponsor.

NCT04649372 — EndoVE endosCopic Treatment for Oesophageal and Gastric canceR · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04929912 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Mirai Medical
Last refreshed: 29 January 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04929912.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing